← Leaderboards
Khosrow Samuel Rezvani
University Of South Dakota
$296,500
Attributed
$296,500
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $74.8K · FY2019–25$100K$75K$50K$25K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$296,500 · 2
By mechanism
R03$296,500 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Primary Neoplasm”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Gregg Kravatz$29,338,050
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Bryan Faller · Decatur Memorial Hospital$23,407,497
Research focus
Primary NeoplasmNovel Therapeutic InterventionMetastatic ColorectalPathway InteractionsMigrationNeoplasm MetastasisExperimental StudyColorectal CancerGrowthMemberAnimalsAnti-CancerMolecularMouse ModelCell LineCell MotilityColonColon Cancer PatientsFluorouracilGenetic TranscriptionMediatingIn VitroCancer CellProteins
Grant awards (4)
"SMART" nanoparticle delivery of veratridine overcomes clinical challenges in metastatic colorectal cancer.$74,750
R03 · FY2025 · CA · contact PI
"SMART" nanoparticle delivery of veratridine overcomes clinical challenges in metastatic colorectal cancer.$74,750
R03 · FY2024 · CA · contact PI
UBXN2A represses migration and invasion of colorectal cancer cells$73,500
R03 · FY2020 · CA · contact PI
UBXN2A represses migration and invasion of colorectal cancer cells$73,500
R03 · FY2019 · CA · contact PI